
In the second part of a two-part interview, Paz Vellanki of Precision for Medicine explains which confirmatory evidence can support a single-trial approval and why she expects FDA's rare disease framework to last.
High-density cell banking accelerates the upstream process by providing concentrated cells to jumpstart a production run. This intensification eliminates many laborious and risky steps used in most labs







